Andrew has made over 1 trades of the Menlo Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 82,999 units of MNLO stock worth $112,049 on 15 March 2019.
The largest trade he's ever made was exercising 82,999 units of Menlo Therapeutics stock on 15 March 2019 worth over $112,049. On average, Andrew trades about 3,609 units every 0 days since 2017. As of 15 March 2019 he still owns at least 82,999 units of Menlo Therapeutics stock.
You can see the complete history of Mr. Saik stock trades at the bottom of the page.
Andrew Saik serves as Chief Financial Officer, Treasurer of the Company. Mr. Saik has over 20 years of accounting, finance, and general management experience at domestic and international companies. He was most recently CFO at PDS Biotechnology, Inc. (formerly Edge Therapeutics). Prior to PDS he was CFO at Vertice Pharma, LLC, a Warburg Pincus-backed company. Previously, he was CFO at Auxilium Pharmaceuticals, Inc., where he helped lead the execution of Auxilium's growth strategy culminating in the sale of the company for $2.6 billion at an 85% share price premium. Prior to Auxilium, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. During his tenure at Endo, he helped complete the acquisition of Paladin Labs and restructured $3B of debt into a new corporate structure. Prior to Endo, Mr. Saik served in senior financial management roles with increasing responsibility at Valeant Pharmaceuticals International, including Senior Vice President, Finance and CFO of the Specialty Pharmaceutical Business which included its dermatology franchise. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.
Andrew Saik is 49, he's been the Chief Financial Officer et Treasurer of Menlo Therapeutics since 2020. There are 7 older and 2 younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.
Andrew's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.
Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr et Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
Menlo Therapeutics executives and other stock owners filed with the SEC include: